Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | CPA3 | P15088 | 2/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9574107 | 0.84 | CPA1 (0.66) | LTA4HCYP1A2CPA1CPA3CPB1 | |
| SCHEMBL7505398 | 0.84 | CPA1 (0.66) | LTA4HCYP1A2CPA1CPA3CPB1 | |
| SCHEMBL7506768 | 0.83 | KMT2A (0.54) | LTA4HABCB1CYP1A2CPA1CPA3 | |
| SCHEMBL13184970 | 0.83 | CYP1A2 (0.52) | LTA4HABCB1CYP1A2CPA1CPA3 | |
| SCHEMBL7506775 | 0.83 | CYP1A2 (0.52) | LTA4HABCB1CYP1A2CPA1CPA3 | |
| SCHEMBL9755831 | 0.83 | KMT2A (0.54) | LTA4HABCB1CYP1A2CPA1CPA3 | |
| SCHEMBL26951776 | 0.83 | LTA4H (0.53) | LTA4HABCB1MAOBCYP1A2HPGD | |
| SCHEMBL30191540 | 0.82 | ABCB1 (0.44) | LTA4HABCB1MAOBCYP1A2CPA1 | |
| SCHEMBL26954314 | 0.81 | MMP1 (0.52) | LTA4HABCB1CYP1A2CPA1CPA3 | |
| SCHEMBL13165582 | 0.80 | CYP1A2 (0.49) | LTA4HABCB1CYP1A2CPA1CPA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | LTA4H 1524/4885ABCB1 1116/4885MMP9 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.